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Functional nonsynonymous single-nucleotide polymorphisms (nsSNPs) of folate metabolism genes can influence the methylation of
tumour suppressor genes, thereby potentially impacting on tumour behaviour. To investigate whether such polymorphisms influence
lung cancer survival, we genotyped 14 nsSNPs mapping to methylene-tetrahydrofolate reductase (MTHFR), methionine synthase
(MTR), methionine synthase reductase (MTRR); DNA methyltransferase (DNMT2), methylenetetrahydrofolate dehydrogenase
(MTHFD1) and methenyltetrahydrofolate synthetase (MTHFS) in 619 Caucasian women with incident disease, 465 with non-small
cell (NSCLC) and 154 with small cell lung cancer (SCLC). The most significant association detected was with MTHFS Thr202Ala, with
carriers of variant alleles having a worse prognosis (hazard ratio (HR)¼1.49; 95% confidence interval: 1.14–1.94). Associations were
also detected between overall survival (OS) in SCLC and homozygosity for MTHFR 222Val (HR¼1.92; 1.03–3.58) and between OS
from NSCLC and MTRR 175Leu carrier status (HR¼1.36; 1.06–1.75). While there is evidence that variation in the folate metabolism
genes may influence prognosis from lung cancer, current data are insufficiently robust to distinguish individual patient outcome.
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Lung cancer is a major cause of cancer mortality worldwide. In the
United Kingdom, it accounts for more than 33000 cancer deaths
each year (Cancer Research UK). Despite improvements in
treatment in recent years, the prognosis from the disease has only
marginally improved with 5-year survival rates for both small
(SCLC) and non-small cell lung cancer (NSCLC), typically being no
better than 15% (Jemal et al, 2002). While the major prognostic
determinant in lung cancer is stage at presentation, there is
variability in survival for patients with same-stage disease. Hence,
it is advantageous to identify further prognostic markers, which
may aid identification of those patients who will benefit from
therapeutic interventions. Furthermore, identifying genes which
influence prognosis has the potential to aid the identification of
pathways that will be targeted for therapeutic interventions.
Aberrant DNA methylation is recognised as being a common
feature of human neoplasia, CpG island hypermethylation and
global genomic hypomethylation occurring simultaneously in
tumours including lung cancers. Moreover, the cellular profile of
DNA hypermethylation has been implicated in progression and
metastasis of lung cancer (Nakamura et al, 2003; Shimamoto et al,
2004).
Variants of folate metabolism pathway (Figure 1) genes such
as functional polymorphisms of 5,10-methylene-tetrahydrofolate
reductase (MTHFR), affect methylation of DNA and tumour
suppressor genes (Kamiya et al, 1998; Paz et al, 2002), thereby
potentially impacting on tumour behaviour. This coupled with
the observation that polymorphisms of this pathway can affect the
efficacy of cytotoxic drugs (Maring et al, 2005) has provided a
strong rationale for evaluating such variants as prognostic factors.
Here, we report the impact of polymorphic variation within the
folate metabolism pathway genes MTHFR, methionine synthase
(MTR), methionine synthase reductase (MTRR), DNA methyl-
transferase (DNMT2), methylenetetrahydrofolate dehydrogenase
(MTHFD1) and methenyltetrahydrofolate synthetase (MTHFS)o n
lung cancer prognosis in 619 patients. We based our analysis on
nonsynonymous single-nucleotide polymorphisms (nsSNPs) as
these alter the amino-acid sequence of expressed proteins and are
most likely to have functional consequences.
METHODS
Patients
Patients with lung cancer were ascertained through the Genetic
Lung Cancer Predisposition Study (GELCAPS). Full details about
the design and conduct of the study can be obtained elsewhere
(Matakidou et al, 2005). Briefly, patients were recruited through
oncology centres in the UK specializing in the management of lung
cancer. To ensure that data and samples were collected from bona
fide lung cancer cases and avoid issues of bias from survivorship,
only incident cases with histologically or cytologically (only if not
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sadenocarcinoma) confirmed primary disease were ascertained.
Demographic characteristics (sex, date of birth, ethnic group, area
of residence and country of birth, smoking history, history of lung
cancer in a first degree relative), treatment and clinical follow-up
were collected from cases using standardized questionnaire and
proformas. The current analysis is based on 619 female patients all
of whom are white Caucasians. Patient characteristics are detailed
in Table 1. Ethical approval for the study was obtained from the
London Multi-Centre Research Ethics Committee (MREC/98/2/67)
in accordance with the tenets of the Declaration of Helsinki. All
participants provided informed consent.
Genotyping
DNA was extracted from EDTA-venous blood samples using a salt
extraction procedure and quantified by Picogreen. The 13 nsSNPs
genotyped, DNMT2 Asp112Tyr, MTHFD1 Lys134Arg, MTHFD1
Arg653Gln, MTHFR Ala222Val, MTHFR Arg594Gln, MTHFR
Thr202Ala, MTR Asp919Gly, MTRR His595Tyr, MTRR Ser175Leu,
MTRR Lys350Arg, MTRR Pro450Arg, MTRR Arg415Cys, MTRR
Ser257Thr. These SNPs were chosen on the basis of being
polymorphic in Caucasians, feasibility of genotyping and estab-
lished functional impact of the sequence changes. Genotyping was
conducted by means of Illumina Sentrix Bead Arrays (Illumina,
San Diego, CA, USA) according to the manufacturer’s protocols
(details available on request).
Statistical methods
Associations between survival and demographic and clinical
variables were assessed by means of the w
2 and Fisher’s exact
tests. Testing for population substructure was based on examining
the distribution of SNP genotypes for evidence of Hardy–
Weinberg disequilibrium. Overall survival (OS) of patients was
the end point of the analyses. Survival time was calculated from the
date of diagnosis of lung cancer to the date of death. Patients who
were not deceased were censored at the date of last contact.
Median follow-up time was computed among censored observa-
tions only. Kaplan–Meier survival curves according to genotype
were generated and the homogeneity of the survival curves was
tested using the log-rank test. Cox regression analysis (Klein and
Moeschberger, 1997) was used to estimate hazard ratios (HRs) and
their 95% confidence intervals (CI) while adjusting for radio-
therapy and stage. Likelihood ratio testing for the inclusion of
covariates and interaction terms was performed to determine the
best-fitting model. For each SNP, HRs were generated using
common allele homozygotes as the reference group (unless
otherwise specified). For polymorphisms with fewer than five
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Figure 1 Schematic representation of one-carbon metabolism. MTHFR, methylenetetrahydrofolate reductase; MTR, methionine synthase; MTRR,
methionine synthase reductase; DNMT, DNA methyltransferase; MTHFD1, methylenetetrahydrofolate dehydrogenase; MTHFS, methenyltetrahydrofolate
synthetase; THF, tetrahydrofolate; DHF, dihydrofolate; dUMP, deoxyuridine monophosphate; dTMP, deoxythymidine monophosphate; SAM, S-adenosyl-
methionine; SAH, S-adenosylhomocysteine. Dotted arrow indicates indirect relationship.
Table 1 Patient demographic and follow-up characteristics
No. of patients (%)
Total 619
Mean age (years) 64.8
Smoking habits
Non-smokers 49 (8)
Smokers 570 (92)
Histology
SCLC 154 (25)
NSCLC 465 (75)
Squamous 180 (30)
Adenocarcinoma 164 (27)
Tumour stage, by histology
SCLC
Limited 66 (43)
Extensive 86 (57)
NSCLC
I 57 (13)
II 68 (15)
III 196 (43)
IV 130 (29)
Median survival time (months) 16.2
Events (deaths) 389 (62.8)
Median survival time, months, by histology and stage
SCLC
Limited 17.8
Extensive 11.1
All stages 13.5
NSCLC
I 49.2
II 31.9
III 16.2
IV 11.5
All stages 17.6
NSCLC¼non-small cell lung cancer; SCLC¼small cell lung cancer.
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were combined with heterozygotes. In addition, to study the
impact of individual SNPs on survival, we evaluated OS as a
function of the number of ‘risk alleles’ carried. In this analysis, risk
was trichotomised into low, medium and high-risk categories.
Owing to the exploratory nature of this study, we reported nominal
statistical associations for all analyses. We recognise that exami-
ning multiple SNPs risks identification of false associations.
However, correction for multiple testing may increase the risk of
type II errors (Perneger, 1998). Accordingly, we present un-
corrected P-values but recognise our exploratory findings require
confirmation in another study. This approach minimises loss of
true positive results but allows false positive results to be identified
(Perneger, 1998; Cuzick, 1999). To adjust for multiple testing, we
multiplied P-values of each individual test statistic by the number
of SNPs in the corresponding gene to obtain a genewide P-value,
the global P-value being the product of the genewide P-value and
the number of genes. Statistical analyses were undertaken using
S-Plus (Version 8, Insightful Corporation, USA). The power to
demonstrate a relationship between SNP genotype and OS was
estimated using sample size formulae for comparative binomial
trials (Farrington and Manning, 1990). In all analyses, a P-value of
0.05 was considered statistically significant. To assess the level of
linkage disequilibrium (LD) between SNPs, we calculated the
pairwise LD measure r
2 between markers mapping to the same
gene using the programme PHASE (Stephens et al, 2001) that
implements the Monte Carlo Markov Chain procedure to estimate
two-locus haplotype frequencies. This information was used to
investigate the relationship between haplotypes and OS.
Bioinformatic analysis
We applied two in silico algorithms, Polymorphism Phenotyping
(PolyPhen) and the Sorting Intolerant from Tolerant to predict the
putative impact of missense variants on protein function(Ng
and Henikoff, 2002; Ramensky et al, 2002). Sorting Intolerant from
Tolerant and PolyPhen scores were classified according to the
established criteria (Ng and Henikoff, 2002; Xi et al, 2004).
RESULTS
Study population and SNP genotype distributions
One hundred and fifty-four of the patients (25%) had SCLC,
somewhat less than half (43%) presenting with limited disease.
Of the 465 patients with NSCLC, 57 (13%) had stage I, 68 (15%)
had stage II, 196 (43%) had stage III and 130 (29%) had stage IV
disease at diagnosis. The majority of patients with limited stage
SCLC had been treated with a combination of radical radiotherapy
and chemotherapy, while all patients received chemotherapy
(Table 1). The main treatment modality for SCLC patients with
extensive disease was chemotherapy. Patients with early stage
NSCLC (stage I and II disease) were mainly treated with surgical
resection of the primary tumour, while about one-third received
chemotherapy and radical radiotherapy. The mainstay treatment
modality of patients with stage III and IV NSCLC was chemo-
therapy. There were 389 (62.8%) deaths in the cohort. Overall the
median survival time (MST) was 16.2 months (range 0.03–60.5
months). There were 13 patients with follow-up time less than 1
month, from whom five died. Patients with SCLC had a MST of
17.8 and 11.1 months, if diagnosed with limited and extensive
disease, respectively. For NSCLC, by stage, MST ranged from 11.5
months in stage IV patients to 49.2 months in the stage I group.
As these survival rates are not significantly different to those
documented in audits of lung cancer prognosis (Cancer Research
UK), there is no evidence that ‘healthy study participant’ selection
will have biased our analyses.
Surgery, any chemotherapy and treatment specifically with
platinum-based compounds did not satisfy the proportional
hazards assumption required for the Cox model. Therefore, we
used a stratified Cox model, stratifying on these covariates. Stage
at presentation, histology, radiotherapy, smoking, family history
of lung cancer and age at diagnosis were initially included as
covariates and backward stepwise selection procedure was
conducted to cover the most parsimonious model. Stage and age
were included as categorical and continuous variables, respec-
tively. Other factors were coded as binary variables. Factors
significantly influencing patient prognosis were stage at presenta-
tion (Po10
 4), histology (P¼0.026) and radiotherapy
(P¼0.0042). Smoking, family history of lung cancer and age at
diagnosis did not impact on survival.
Relationship between SNP genotype and prognosis
For most SNPs genotyped (92%), minor allele frequencies (MAF)
were 5% or higher. One SNP was however, observed at
comparatively low frequencies (i.e. having MAF o5%). There
was no evidence in the data set for population stratification based
on testing the distribution of SNP genotypes for Hardy–Weinberg
disequilibrium. Thirteen nsSNPs in six genes were assayed. Only
SNPs S257T, R415C and P450R, and SNPs H595Y and K175L, all
mapping to MTRR, were in strong LD (i.e. r
2¼1.0 and r
2¼0.81,
respectively). Hence, the relationship between SNP haplotype and
prognosis was restricted to this locus.
There was no correlation between the SNP genotype and
pathological parameters, (stage and histology), but in view of the
differences in biology of NSCLC and SCLC we also examined for
relationships between genotypes and prognosis in the two cell
types separately. Table 2 details the relationships between SNP
genotype and OS from lung cancer obtained from Cox regression
analysis.
Significant associations were identified between polymorphic
variation in MTHFS, MTHFR and MTRR. Under the Cox
proportional hazards model, the HRs for OS from all lung cancer
associated with MTHFS Thr202Ala heterozygosity, homozygosity
and carrier status were: 1.53 (95% CI: 1.17–2.01), 1.04 (95% CI:
0.38–2.84) and 1.49 (95% CI: 1.14–1.94), respectively. Kaplan–
Meier estimates demonstrated that carriers had a shorter MST
than patients with the wild-type genotype (MST of 12.9 and 16.7
months, respectively; P¼0.052; Figure 2). The HRs for OS from
NSCLC associated with MTHFS Thr202Ala heterozygosity, homo-
zygosity and carrier status were 1.4 (95% CI: 1.02–1.92), 1.45 (95%
CI: 0.44–4.71) and 1.4 (95% CI: 1.06–1.91), respectively. The HRs
for OS from SCLC associated with MTHFS Thr202Ala carrier
status was 1.96 (95% CI: 1.17–3.30). For SCLC there were too few
homozygotes, hence, these data were pooled with heterozygotes.
Variation in MTHFR defined by Ala222Val appeared to influence
OS for SCLC in a recessive fashion with HR associated with
heterozygote, homozygote and carrier status being 1.08 (95% CI:
0.70–1.68), 1.92 (95% CI: 1.03–3.58) and 1.20 (95% CI: 0.79–1.82),
respectively. For this group, Kaplan–Meier estimates showed that
variant homozygotes had a shorter MST than patients with other
genotypes (MSTs of 10.3 and 14.3 months, respectively; P¼0.025,
Figure 2). MTHFR Arg594Gln influenced OS with HR associated
with carrier status being 0.68 (95% CI: 0.46–1.00), and 0.60 (95%
CI: 0.37–0.95) in all lung cancer and NSCLC, respectively. For
NSCLC, Kaplan–Meier estimates showed that variant carriers had
a longer MST than patients with other genotypes (25.4 and 16.2
months, respectively; P¼0.02; Figure 1). There was evidence that
carrier status for MTRR Ser175Leu is associated with a poorer
prognosis (HR¼1.14; 95% CI: 0.92–1.41) albeit borderline
significance in all cancers but significant in NSCLC (HR¼1.36;
95% CI: 1.06–1.75). For NSCLC patients, MST in carriers was
15.9 compared to 19.8 months in patients with other genotypes
(P¼0.09, Figure 1). A number of other variants were also
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sTable 2 Relationship between overall survival from lung cancer and polymorphisms in folate metabolism genes
All cancer NSCLC SCLC
Survival Survival Survival
Gene
amino acid Genotype
Dead
(n¼375)
Alive
(n¼219) HR 95% CI
Dead
(n¼271)
Alive
(n¼171) HR 95% CI
Dead
(n¼104)
Alive
(n¼48) HR 95% CI
DNMT2 +/+ 259 152 — 188 120 — 71 32 —
Asp112Tyr +/  111 64 0.94 0.75–1.19 78 49 0.95 0.72–1.25 33 15 0.97 0.63–1.50
 /  5 3 0.75 0.31–1.83 5 2 0.81 0.33–1.98 0 1 —
+/  and  /  0.93 0.74–1.17 0.94 0.72–1.23 0.97 0.63–1.50
MTHFD1 +/+ 257 146 — 186 114 — 71 32 —
Lys134Arg +/  105 64 0.97 0.77–1.22 74 51 1.01 0.76–1.33 31 13 0.83 0.53–1.30
 /  13 9 1.46 0.83–2.57 11 6 1.55 0.83–2.87 2 3 1.22 0.28–5.23
+/  and  /  1.01 0.81–1.26 1.06 0.81–1.38 0.85 0.55–1.32
MTHFD1 +/+ 94 60 — 67 51 — 27 9 —
Arg653Gln +/  203 113 0.88 0.68–1.12 153 88 0.96 0.71–1.29 50 25 0.86 0.52–1.40
 /  78 46 0.78 0.58–1.07 51 32 0.76 0.52–1.11 27 14 1.2 0.69–2.06
+/  and  /  0.85 0.67–1.08 0.9 0.68–1.20 0.96 0.61–1.52
MTHFR +/+ 153 100 — 115 78 — 38 22 —
Ala222Val +/  181 100 1.09 0.88–1.36 130 77 1.09 0.84–1.41 51 23 1.08 0.70–1.68
 /  41 19 1.37 0.96–1.95 26 16 1.2 0.77–1.86 15 3 1.92 1.03–3.58
+/  and  /  1.13 0.91–1.40 1.1 0.86–1.42 1.2 0.79–1.82
MTHFR +/+ 347 192 — 252 148 — 95 44 —
Arg594Gln +/  28 26 0.68 0.46–1.00 19 22 0.6 0.37–0.95 9 4 0.95 0.48–1.89
 /  01 — 01 —0 0 —
+/  and  /  0.68 0.46–1.00 0.6 0.37–0.95 0.95 0.48–1.89
MTHFS +/+ 305 182 — 220 142 — 85 40 —
Thr202Ala +/  66 33 1.53 1.17–2.01 48 26 1.4 1.02–1.92 18 7 1.96 1.17–3.30
 /  4 4 1.04 0.38–2.84 3 3 1.45 0.44–4.71 1 1 —
+/  and  /  1.49 1.14–1.94 1.4 1.02–1.91 1.96 1.17–3.30
MTR +/+ 248 138 — 183 104 — 65 34 —
Asp919Gly +/  110 70 0.94 0.75–1.19 76 59 0.88 0.67–1.15 34 11 1.1 0.72–1.69
 /  17 11 1.44 0.88–2.36 12 8 1.35 0.75–2.45 5 3 1.65 0.65–4.15
+/  and  /  0.99 0.80–1.23 0.92 0.71–1.19 1.15 0.77–1.73
MTRR +/+ 302 172 — 219 133 — 83 39 —
His595Tyr +/  70 45 1.03 0.79–1.34 51 36 0.99 0.73–1.35 19 9 1.11 0.67–1.82
 /  3 2 1.02 0.32–3.25 1 2 — 2 0 —
+/  and  /  1.03 0.79–1.34 0.99 0.73–1.35 1.11 0.67–1.82
MTRR +/+ 144 92 — 103 77 — 41 15 —
Ser175Leu +/  177 94 1.18 0.94–1.49 125 71 1.42 1.09–1.87 52 23 0.81 0.52–1.26
 /  54 33 1.01 0.74–1.39 43 23 1.21 0.85–1.74 11 10 0.62 0.31–1.23
+/  and  /  1.14 0.92–1.41 1.36 1.06–1.75 0.77 0.50–1.17
MTRR +/+ 286 164 — 205 126 — 81 38 —
Lys350Arg +/  86 51 1.09 0.85–1.39 65 42 1.09 0.82–1.45 21 9 0.91 0.56–1.49
 /  3 4 0.79 0.25–2.51 1 3 — 2 1 —
+/  and  /  1.07 0.84–1.37 1.09 0.82–1.45 0.91 0.56–1.49
MTRR +/+ 356 210 — 259 164 — 97 46 —
Pro450Arg +/  19 9 1.38 0.87–2.20 12 7 1.41 0.78–2.53 7 2 1.32 0.60–2.88
 /  00 — 00 —0 0 —
+/  and  /  1.38 0.87–2.20 1.41 0.78–2.53 1.32 0.60–2.88
MTRR +/+ 356 210 — 259 164 — 97 46 —
Arg415Cys +/  19 9 1.38 0.87–2.20 12 7 1.41 0.78–2.53 7 2 1.32 0.60–2.88
 /  00 — 00 —0 0 —
+/  and  /  1.38 0.87–2.20 1.41 0.78–2.53 1.32 0.60–2.88
MTRR +/+ 356 210 — 259 164 — 97 46 —
Ser257Thr +/  19 9 1.38 0.87–2.20 12 7 1.41 0.78–2.53 7 2 1.32 0.60–2.88
 /  00 — 00 —0 0 —
+/  and  /  1.38 0.87–2.20 1.41 0.78–2.53 1.32 0.60–2.88
CI¼confidence interval; DNMT2¼DNA methyltransferase; HR¼hazard ratio; MTHFD1¼methylenetetrahydrofolate dehydrogenase; MTHFR¼methylene-tetrahydrofolate reductase; MTR¼methionine synthase;
MTRR¼methionine synthase reductase; NSCLC¼non-small cell lung cancer; SCLC: small cell lung cancer.
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sassociated with OS (Table 2), but none were individually
significant.
Evaluating OS as a function of the number of ‘risk alleles’
provided no evidence of an interaction between SNPs (data not
shown). Finally, we examined for potential interactive effects
between SNPs, response to platinum-based chemotherapy and
prognosis. None showed nominally significant interactions at the
5% level.
DISCUSSION
Major strengths of our study are its large size, the fact that it is
population-based, included only patients with incident disease,
and has involved the systematic follow-up of patients. We are
mindful that it is desirable that studies aimed at identifying
prognostic markers should be conducted within the context of a
clinical trial to minimise bias. Although bias from non-uniform
treatment is a potential confounder in studies of some solid
tumours, the management of lung cancer is relatively uniform in
the UK, as there are only a restricted number of effective
chemotherapeutic agents and prognosis is uniformly poor.
Support for this assertion is provided by the fact that survival
rates observed in our patient cohort were not different to those
expected. It is therefore unlikely that any spurious influences as a
consequence of study design will have impacted significantly on
our findings. It is well known that the allele frequencies of many
SNPs vary among different populations. As our analysis was
restricted to white patients, our study findings are unlikely to be
confounded by population stratification. The main limitation of
our study is the ability to pursue an in-depth examination of the
effect of non-genetic factors such as circulating folate levels, which
may interact with genotype in defining the clinical behaviour of
tumours.
Despite such limitations in this study, we have observed
significant evidence for associations between survival and varia-
tion in MTHFR, MTHFS and MTRR. Our observation that
polymorphic variation in the folate metabolism genes influences
cancer prognosis is not without precedent (Alberola et al, 2004).
We fully acknowledge that we have not captured all variation
defined by nsSNPs mapping to all of the folate metabolism genes
but our selection was restricted to validated SNPs that could be
robustly genotyped using the analytical platform we employed. For
example, it would have been desirable to have genotyped nsSNPs
mapping to DNMT1 and DNMT3b, given previously published data
implicating variation in these genes in development and prognosis
of lung cancer (Kassis et al, 2006; Kim et al, 2006; Wang et al,
2006). However, to date only two common (MAF 40.05) validated
nsSNPs map to DNMT1 (Ile311Val and His97Arg) and both
unfortunately had low designability for the genotyping platform we
employed, thereby precluding evaluation.
We evaluated nsSNPs on the basis that each has the capacity to
directly affect the function of expressed proteins, implying a higher
probability of being directly causally related to susceptibility.
There is good evidence that MTHFR Ala222Val directly affect the
function of the expressed protein. For SNPs such as MTHFS
Thr202Ala and MTRR Ser175Leu, substitutions are not predicted
to be benign. Although such in silico predictions about the
functional consequences of amino-acid changes are not definitive,
these algorithms have been demonstrated in benchmarking studies
to successfully categorise 80% of amino-acid substitutions (Savas
et al, 2004; Xi et al, 2004).
The nature of our study precluded us from formally evaluating
SNPs in relation to response to radiotherapy as this was only
administered to a small number of patients. Similarly only a small
number of patients did not receive platinum-based chemotherapy
limiting our ability to robustly detect interactions between this
type of therapy, genotype and prognosis. Although there may be
differences between NSCLC and SCLC, which may reflect
differences in biology of the tumour types, our data did not
provide real evidence that folate metabolism variation plays a
major role in defining differences in prognosis between these
tumour types.
In studies of the type we have conducted, there is the issue of
adjustment for multiple comparisons. We assessed 13 polymor-
phisms in seven genes but because more than one polymorphism
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Figure 2 Kaplan–Meier curves for lung cancer patients. (A) Relationship between MTHFS Thr202Ala genotype and prognosis from all lung cancer; (B)
relationship between MTHFR Ala222Val genotype and prognosis from SCLC; (C) relationship between MTHFR Ala222Val genotype and prognosis from
NSCLC; (D) relationship between MTRR Ser175Leu genotype and prognosis from NSCLC. The solid line depicts the survival curve for the reference group.
þ/þ, þ/  and  /  refer to the common homozygotes, heterozygotes and rare homozygotes, respectively.
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for MTHFS Thr202Ala, the statistical threshold for global
significance is 0.007.
Issues of power are also relevant to the formulation of studies
seeking to identify polymorphic variants influencing cancer
prognosis. The magnitude of any difference in prognosis
associated with individual SNPs is likely to be at best modest
hence stipulating significance levels of B10
 4 or less to adjust for
multiple testing is inherently unrealistic. For example, for an
analysis to have 80% power to demonstrate a 5% difference in
survival, which is clinically relevant, would require at least 4800
patient samples to be analysed even if the frequency of the at-risk
genotype is 50% stipulating such significance levels. For less
frequent genotypes, samples sizes would be impossibly large. On
this basis the imposition of very stringent P-values (as advocated
in genome-wide case–control studies) to outcome studies is
questionable creating the serious issue of generating a raft of type
II errors (Perneger, 1998).
Despite the strong biologic plausibility and consistency with
literature for several individual associations as discussed herein,
some of these associations may be false positives as a result of the
inherent pitfalls of the candidate gene approach. Hence, individual
associations reported in this article must inevitably be interpreted
with caution. Nevertheless, even for those true associations, it is
unlikely that any individual SNP would have sufficient power to
predict clinical outcomes in a disease as complex as cancer. In
this context, combined analyses of two or more SNPs in the same
pathway are likely to have superior potential to assist in
distinguishing different outcome patterns among patients with
the same stage disease as even 5–10% differences in prognosis are
relevant in a disease. Furthermore, it is plausible that the impact of
variation in the folate metabolism genes is likely to be best seen in
situations where the pathway plays a major role in defining the
efficacy of chemotherapeutic agents in cancers amenable to
treatment with agents such as pyrimidine-antagonists (Maring
et al, 2005).
In conclusion, however attractive the notion that polymor-
phisms of the folate metabolism pathway genes are in defining
cancer prognosis, their role in lung cancer on the basis of our data
is minor at best and they are unlikely to have clinical utility.
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